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Introduction
 The mortality rate due to cancer has continued to in-
crease over the last 50 years in Japan.  Within the last 
25 years, carcinoma has become the leading cause of 
death in Japan, with the rate of people dying from oral 
and pharyngeal carcinoma increasing about 3-fold1. 
Since some types of cancer develop from precancerous 
lesions, early diagnosis and timely treatment of such 
precancerous lesions can prevent their malignant trans-
formation.  Oral leukoplakia is noted to be the most 
common premalignant lesion of the oral mucosa2 and it 
is therefore important to clarify its clinical and histo-
pathological characteristics.  However, the mechanism 
of malignant transformation remains unknown.  In this 
review, we focus on the relationship between the clinical 
and histopathological characteristics of oral leukoplakia 
and its malignant transformation.
Deﬁ nition of oral leukoplakia
 Oral leukoplakia is deﬁ ned as a predominantly white 
lesion of the oral mucosa that can not be characterized 
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as any other deﬁ nable lesion2,3.  This very broad deﬁ ni-
tion has led a number of clinicians to report their own 
classiﬁ cation criteria, although the general concept and 
the essential substance of oral leukoplakia have re-
mained unchanged for a long time2–6.  Pindborg et al.2 
state that leukoplakia should be used only as a clinical 
term, and we assert that ﬁ nal diagnosis is conﬁ rmed 
histopathologically by biopsy.  Lesions that are diag-
nosed histologically as cancer are to be excluded from 
cases of leukoplakia.
Clinical classiﬁ cation of oral leukoplakia
 The clinical and histological aspects of oral leukopla-
kia were rarely reported prior to the ﬁ ndings of Pin-
dborg et al.7.  Axell et al.3 and Pindborg et al.2 classiﬁ ed 
homogenous and non-homogenous leukoplakias into 4 
subtypes for each.  Homogenous types were classiﬁ ed 
into ﬂ at, corrugated, wrinkled, and pumice types, 
whereas non-homogenous types were classiﬁ ed as ver-
rucous, nodular (speckled), ulcerated, and erythroleuko-
plakia types.  The pumice type of leukoplakia was most-
ly associated with tobacco smoking38.  Generally, non-
homogenous types are considered to show a greater risk 
of malignant transformation2.  We previously classiﬁ ed 
oral leukoplakia into 4 clinical types8 : type I, ﬂ at white 
patch or plaque without red component ; type II, ﬂ at 
white patch or plaque with red components ; type III, 
slightly raised or elevated white plaque ; and type IV, 
markedly raised or elevated white plaque (Table 1, Fig. 
1 (A–D).  Fig. 2 (A–C) are representative examples of 
epithelial dysplasia we used in the studies8,19,20,33,34.
Relationship between clinical classiﬁ cation of 
leukoplakia and epithelial dysplasia
 Sharp9, Rotter et al.10 and Hahn et al.11 reported that 
verrucous leukoplakia was often associated with epithe-
lial dysplasia, and Ackermann and Johnson12 and Sha-
fer and Waldron13 stated that a pinkish-gray or red 
granular appearance was often associated with epitheli-
al dysplasia or carcinoma in situ.  Pinborg et al.7 con-
ﬁ rmed that speckled leukoplakia, which is characterized 
by the presence of white patches in a nodular form or 
white lesions interspersed with erythematous area, was 
often associated with epithelial dysplasia or carcinoma. 
These ﬁ ndings were supported by subsequent reports 
showing the association of non-homogenous leukoplakia 
with epithelial dysplasia14–16.  Sugár and Bánóczy17, us-
ing a different clinical classiﬁ cation, also reported the 
association of leukoplakia erosiva and leukoplakia ver-
rucosa with epithelial dysplasia.  Because the clinical 
manifestations of oral leukoplakia in Japan did not ex-
actly match these classiﬁ cation systems (there are few 
cases with nodular appearance in Japan), we construct-
ed our own classiﬁ cation system8, as mentioned above, 
in which type II oral leukoplakia included an ulcerated 
type or erythroleukoplakia18.  We found that the occur-
rence of epithelial dysplasia was highly associated with 
type II leukoplakia, followed by type III or IV (Table 
2)19–20.
Malignant transformation rate versus cumulative 
malignant transformation rate
 Previously reported rates of malignant transforma-
tion of oral leukoplakia range from 0.13 to 17.0% (Table 
3)18,20–33.  Our recent study showed that the malignant 
transformation rate of oral leukoplakia was 7.9% (35 of 
444 patients with oral leukoplakia)20.  However, the rate 
of malignant transformation may increase when pa-
tients are followed over a longer term or may decrease 
when patients are lost early to follow-up.  The resulting 
rate of malignant transformation can therefore be unre-
liable.  To eliminate this bias, the calculation of cumula-
tive survival rate is necessary to determine the cumula-
tive malignant transformation rate.  The cumulative 
transformation rates reported by some researchers are 
shown in Table 4.  The 5-year cumulative malignant 
transformation rate ranged from 1.2 to 14.5 %25,32,34–37.
Table 1　Clinical classiﬁ cation of oral leukoplakia8
Type I :
Type II :
Type III :
Type IV :
ﬂ at, white patch/plaque without red components
ﬂ at, white patch/plaque with erosion or red components
slightly raised or elevated white patch/plaque
markedly raised or elevated white patch/plaque
We classiﬁ ed oral leukoplakia into 4 clinical types based on our experience.
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Fig. 1　Clinical features of leukoplakia can be classiﬁ ed into four types, type I (A) of the 
maxillary gingiva showing ﬂ at white patch, type II (B) of the tongue showing 
white patch and plaque with erosion, type III (C) of the buccal mucosa showing 
slightly elevated white plaque, and type IV (D) of the buccal mucosa showing 
markedly elevated white plaque with partly granular appearance.
Fig. 2　Histopathological features of leukoplakia. Mild dysplasia (A) : Slight irregular epithelial ar-
chitecture limited to the lower third of the epithelium. Basal-parabasal cells show hyperchro-
matic large nuclei and loss of polarity. Moderate dysplasia (B) : Hyperplastic epithelium with 
increased number of polymorphic cells extends up to two thirds of the epithelium, and cellu-
lar atypia is more pronounced with nuclear pleomorphism. Severe dysplasia (C) : The atypical 
basal-like and spinous-like cells occupy almost all epithelial layers. Squamous epithelium is 
of variable thickness with drop-shaped rete ridges and prominent cytologic atypia.
(A) (B)
(C) (D)
(A) (B)
(C)
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Gender and malignant transformation
 A large number of reports of oral leukoplakia, regard-
less of malignant transformation, identiﬁ ed a male pre-
dominance13,16,17,20,21–23,28,29,31,38,39, with a female predomi-
nance reported in only a few18,32,36.
 Sex predilection for malignant transformation is un-
clear because of the conﬂ icting data reported in the lit-
erature.  Lind30 reported that females were more prone 
Table 2　Incidence of epithelial dysplasia in each clinical type of oral leukoplakia20
Type Cases
Non
-dysplasia
Dysplasia
Total
No. of
dysplasia (%)Mild Moderate Severe
I
II
III
IV
328
 71
 24
 21
203
 13
 11
  7
 86
 31
 10
 11
30
16
 2
 1
 9
11
 1
 2
125
 58
 13
 14
　(38.1)
　(81.7)
　(54.2)
　(66.7)
Total 444 234 138 49 23 210
(%) (52.7) (31.1) (11.0) (5.2) 　(47.3)
* Statistically signiﬁ cant differences between incidence of epithelial dysplasia in type I and type II 
(p＜0.01), and between type I and types II, III and IV (p＜0.01).
Table 4　Cummulative malignant transformation rates of oral leukoplakia
Authors (Year)　 Country No. of patients 5-year (%) 10-year (%) Follow-up period (mean)
Einhorn et al.  (1967)25
Amagasa et al.  (1982)33
Inoue et al.  (1985)35
Kirita et al.  (1995)36
Schepman et al.  (1998)32
Kawabe et al.  (2001)37
USA
Japan
Japan
Japan
Netherlands
Japan
782
169
 75
102
166
237
 1.6
12.0
 4.5
 1.2
14.5
 4.7
 2.4
21.0
 9.7
 6.6
29.0
11.1
1–20y
1–20y
7m-26y (12yr8m)
7m-12y1m (6y2m)
6m-16y9m 【6y2m】
(56.5± 43.4m)
【median】
Table 3　Malignant transformation of oral leukoplakia
Authors Country Year No. of patients
Malignant 
transformation (%)
Observation 
periods (Years)
Silverman et al.21
Gupta et al. 22
Mehta et al.23
Gupta et al.22
Roed-Peterson et al.24
Einhorn et al.25
Pinborg et al.26
Kramer et al.27
Silverman et al.28
Bánócy29
Amagasa et al.33
Amagasa et al.20
Lind30
Gangadharan et al.31
Schepman et al.32
Silverman et al.18
India
India
India
India
Denmark
Sweden
Denmark
England
USA
Hungary
Japan
Japan
Norway
England
Holland
USA
1976
1980
1972
1980
1971
1967
1968
1969
1968
1977
1989
1999
1987
1971
1997
1984
4762　
360
117
410
331
782
248
187
117
670
169
444
157
626
166
257
  0.13
 0.3
 0.8
 2.2
 3.6
 4.0
 4.4
 4.8
 6.0
 6.0
 7.1
 7.9
 8.9
10.0
12.0
17.5
2
1–10 (7)
10
1–10 (8)
1– (4.3)
1–20
1– 9
1–16
1–11
1–30
1–20
1–29
6–
1–19
6M–17 (2.7)
6M–39 (7.2)
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to undergo malignant transformation than males, and 
epithelial dysplasia was more frequent in females.  This 
was further supported by the ﬁ ndings of other au-
thors26,28,29,32.  The risk factors for malignant transfor-
mation were listed by Schepman et al. (1998)32 as fol-
lows : female gender, absence of smoking habits in 
women (p＜0.05), and non-homogenous clinical aspect 
(p＜0.01).  However, other reports found a greater ma-
lignant transformation potential among males in India, 
particularly in association with chewing tobacco and 
smoking habits21–23.  In our study, the malignant trans-
formation rate (11.2%) of females with leukoplakia was 
higher than that (6.2%) of males (Table 5).  However, 
this did not represent a signiﬁ cant statistical difference 
for gender20.
Age and malignant transformation
 Over a 30-year period, Bánóczy29 identiﬁ ed a greater 
prevalence of leukoplakia among the 50–60 year-old 
group, but the risk of malignant transformation was 
highest among the 60–70 year-old group.  Our study 
also showed a statistically signiﬁ cant difference of ma-
lignant transformation rate between the over 50-year-
old group and the under 50-year-old group (Table 5)20, 
supporting the ﬁ ndings of Chiesa et al.40 with statistical 
signiﬁ cance.  The relationship between higher malig-
nant transformation rate and older patients may sug-
gest that patients with longer exposure to oral leukopla-
kia are more prone to malignant transformation.
Site and malignant transformation
 Our ﬁ ndings showed that the malignant transforma-
tion rate of oral leukoplakia of the tongue was signiﬁ -
cantly higher than that of the buccal mucosa and that of 
other sites (Table 6)20.  These results concur with those 
of other studies conducted in Japan35–37.  Some authors 
also reported that leukoplakia of the tongue and ﬂ oor of 
the mouth exhibited a high risk of malignant transfor-
mation24,41,42.  This is in contrast to other reports identi-
fying the buccal mucosa and labial commissure as the 
areas with the highest malignant transformation rate, 
particularly for patients with tobacco chewing and 
smoking habits among Indian villagers21,22,26.  On the 
other hand, some reports showed that no oral subsites 
are associated with a high risk of malignant transfor-
mation32,43.  These differences might be related to the 
presence or absence of various oral habits of certain 
groups or populations.
Clinical type and malignant transformation
 Since Pinborg et al.7 showed that speckled leukopla-
kia was often associated with epithelial dysplasia and 
carcinoma, various reports about the correlation of the 
clinical type of oral leukoplakia with malignant trans-
formation have been published23,26,32,44,45.  Sugár and 
Bánóczy17 reported that erosive leukoplakia showed the 
highest potential of malignant transformation in com-
parison to simplex leukoplakia.  Holmstrup et al.43 ex-
amined 236 patients with leukoplakia and using logistic 
regression analysis showed a 7-fold increase in the risk 
of malignant transformation (OR＝7.0) in non-homoge-
Table 5　 Incidence of malignant transformation of oral leukoplakia according to 
sex and age20
Age Male Female Total (%)　　　　
18–19
20–29
30–39
40–49
50–59
60–69
70–79
80 　
 0/  2
 0/ 12
 1/ 24
 1/ 52
 6/ 90
 7/ 62
 1/ 29
 1/  4
 0/  0
 1/  7
 1/ 14
 1/ 34
 6/ 58
 7/ 31
 1/ 23
 1/  2
 0/  2
 1/ 19
 2/ 38
 2/ 86
12/148
14/ 93
 2/ 52
 2/  6
(0.0)
(5.3)
(5.3)
(2.3)
(8.1)
(15.1)
(5.8)
(33.0)
Total
(%)
17/275
(6.2)
18/169
(11.2)
35/444
(7.9)
* Statistically signiﬁ cant difference of malignant transformation rate between the 
over 50-year-old group and the under 50-year-old group (p＜0.05).
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nous leukoplakia as compared to homogenous leukopla-
kia, and a 5.4-fold increase in the risk when the lesions 
exceeded 200 mm2.  In our classiﬁ cation, malignant 
transformation rate was the highest in type II lesions 
(21.4%), followed by type III (6.9%) and type IV (6.7%), 
with type I (2.8%) the lowest (Table 6)20.  There were 
statistical differences between type II and type I, be-
tween type II and types III and IV, and between type I 
and types II, III and IV.  However, there was no statisti-
cal difference between type I and types III and IV20. 
Despite the fact that various criteria are used to evalu-
ate the clinical types of oral leukoplakia, we concur that 
leukoplakia with red components and the so-called non-
homogenous leukoplakia, including verrucous and 
raised type, carry a higher risk of malignant transfor-
mation.
Epithelial dysplasia and malignant transforma-
tion
 The incidences of malignant transformation of oral 
leukoplakia with and without dysplasia are listed in Ta-
ble 715,16,18,20,46–48.  Our study20 showed that 28 (13.3%) of 
210 patients having leukoplakia with epithelial dyspla-
sia underwent malignant transformation, though only 7 
(3.0%) of 234 patients with leukoplakia showing no epi-
thelial dysplasia had malignant transformation.  There 
was a statistical difference between the malignant 
transformation rate of the oral leukoplakia with epithe-
lial dysplasia and that without dysplasia.  However, 
there was no correlation between the malignant trans-
formation rate and degree of epithelial dysplasia (Table 
8)20, because the leukoplakias with moderate and severe 
dysplasia were selectively and immediately excised. 
Some studies also showed that the malignant transfor-
mation rate of oral leukoplakia with epithelial dysplasia 
was higher than that of oral leukoplakia without epi-
thelial dysplasia18,48.  Kawabe et al.37, using the Cox pro-
portional hazard model, reported that only the presence 
of epithelial dysplasia and a previous history of oral 
cancer are signiﬁ cant predictors for the malignant 
transformation of leukoplakia.
 On the contrary, Holmstrup et al.43 reported that the 
presence of epithelial dysplasia in oral leukoplakia was 
not a statistically signiﬁ cant factor for malignant trans-
formation based on logistic regression analysis.  They 
described that this factor may, however, vary in levels of 
signiﬁ cance due to the subjectivity of diagnosis of epi-
thelial dysplasia49–51
 The periods from initial biopsy of oral leukoplakia to 
malignant transformation were examined in our study 
Table 6　Incidence of malignant transformation of 601 lesions of oral leukoplakias according to clinical type and site20
Site I II III IV Total (%)
Tongue  8/ 93
(8.6)
14/40
(35.0)
0/ 6 2/ 7
(28.6)
24/143 (16.4)
Buccal  1/ 89
(1.1)
 4/23
(17.4)
1/ 4
(25.0)
0/ 9 6/125 (4.8)
Lower gum  4/129
(3.1)
 0/7 1/7
(14.3)
0/ 7 5/150 (3.3)
Upper gum  0/ 80  0/ 5 0/ 3 0/ 5 0/93 (0.0)
Palate  0/ 34  0/ 5 0/ 4 0/ 2 0/45 (0.0)
Floor of mouth  0/ 22  0/ 2 0/ 4 0/28 (0.0)
Lips  0/  8  0/ 1 0/ 1 0/10 (0.0)
Oropharynx  0/  3  0/ 1 0/ 4 (0.0)
Total 13/458
(2.8)
18/84
(21.4)
2/29
(6.9)
2/30
(6.7)
35/601
(5.8)
*  Statistically signiﬁ cant differences of malignant transformation rate of leukoplakia between the tongue and 
buccal mucosa (p＜0.01), and between the buccal mucosa and other sites (p＜0.01). There were statistically sig-
niﬁ cant differences between type II and type I (p＜0.01), and between type II and types III and IV (p＜0.05).
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(Table 9)20.  The shortest (less than 5 years) malignant 
transformation periods were observed for oral leukopla-
kia with severe dysplasia, followed by moderate epithe-
lial dysplasia, mild dysplasia and no dysplasia from 5 
years to a maximum 25 years 6 months.  These ﬁ ndings 
suggest that there is a relationship between severity of 
epithelial dysplasia and the period of malignant trans-
formation of oral leukoplakia to cancer development.
Etiologic factors of oral leukoplakia
 The pathogenesis of oral leukoplakia is likely to be 
associated with oral habits since many studies showed a 
relationship of smoking with leukoplakia and malignant 
transformation14,21,45,51.  A prospective epidemiologic 
house-to-house survey for randomly extracted samples 
in India showed that the annual incidence rate of leuko-
plakia was highest in the group with mixed tobacco 
habits (chewing and smoking) and was lowest in the 
group without any tobacco habits52.  The rate of malig-
Table 7　Malignant transformation rates of oral leukoplakia with and without dysplasia as reported in the literature
Authors  (Year)　
No.of leukoplakia with 
epithelial dysplasia
No. of leukoplakia without 
epithelial dysplasia
Follow-up 
periods (yr)
No. of 
cases
No. of malignat 
transformation (%)
No. of 
cases
No. of malignant 
transformation (%)
Mincer et al.  (1972)15
Banoczy and Csiba  (1976)16
Pindborg et al.  (1977)46
Silverman et al.  (1984)18
Lumerman et al.  (1995)47
Amagasa et al.  (1999)20
Cowan et al.  (2001)48
 45
 68
 61
 22
 44
210
165
 5 (11.1)
 9 (13.2)
 4  (6.6)
 8 (36.4)
 7 (16.0)
28 (13.3)
25 (15.0)
 235
 234
1182
23 (9.8)
 7 (3.0)
12 (1.0)
Up to 8
1–20 (mean 6.3)
Up to 7
Mean 8.1
Up to 6.5
1–25
over 20
Total 615 86 (13.9) 1651 42 (2.6)
The malignant transformation rates of leukoplakia with dysplasia were higher than those without dysplasia.
Table 8　 Incidence of malignant transformation of oral leukopla-
kias according to epithelial dysplasia20
Epithelial dysplasia No. of cases
No. of malignant
transformation (%)
None
Mild
Moderate
Severe
234
138
 49
 23
7  (3.0)
18 (13.0)
7 (14.3)
3 (13.0)
Total 444 35  (7.9)
Table 9　 Malignant transformation periods of 35 cases of oral leukoplakias accord-
ing to epithelial dysplasia20
Epithelial dysplasia Period (years)
≦ 2 ≦ 5 ≦ 7 ≦ 10 10＜ Total
None
Mild
Moderate
Severe
0
4
1
1
 0
 6
 4
 2
1
3
2
0
5
2
0
0
1
3
0
0
 7
18
 7
 3
Total
(%)
6
(17.2)
12
(34.3)
6
(17.1)
7
(20.0)
4
(11.4)
35
(100.0)
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nant transformation was also highest in oral leukopla-
kia associated with tobacco chewing habits.  A case con-
trol study performed in Taiwan showed that adjusted 
odds ratios for betel nut chewing and smoking on the 
occurrence of leukoplakia were 17.43 (95% CI 1.94–
1 56.27) and 3.22 (95% CI 1.06–9.78), respectively53. 
Moreover, the cessation of smoking is expected to reduce 
leukoplakia cases by 36%, while the elimination of betel 
nuts will prevent leukoplakia by 62% and malignant 
transformation to oral carcinoma by 26% in the under-
lying population53.
 Some authors have reported different ﬁ ndings, how-
ever.  Schepman et al.32 reported that the parameters 
associated with an increased risk of malignant transfor-
mation were female gender (p＜0.025), absence of smok-
ing habits in women (p＜0.05), and a non-homogeneous 
clinical aspect (p＜0.01).  Silverman et al.18 also showed 
that high risks for malignant transformation included 
non-smoking patients, the clinical presence of erythro-
plasia (erythroleukoplakia), and a clinical verrucous-
papillary hyperkeratotic pattern.
 Human papilloma virus (HPV) may also be implicated 
in oral leukoplakia as an infecting agent54–60.  Compared 
with normal oral mucosa, HPV is detected frequently in 
oral dysplasia lesions and carcinoma, and HPV infection 
with a high-risk genotype is well known to be an inde-
pendent risk factor for oral cancer59.  The consistent ab-
sence of the malignant-type HPV in the betel quid-relat-
ed lesions suggests that HPV plays only a minor role in 
betel quid-related carcinogenesis, although an associa-
tion between the benign-type HPV with betel quid 
chewing may contribute to malignant transformation of 
oral mucosa60.
 From the above ﬁ ndings, it is suggested that there 
are several routes to malignant transformation of oral 
leukoplakia, including the transformations induced by 
the carcinogens in betel quid chewing and smoking, and 
by HPV infection.  Further studies remain to be done.
Treatment
 The lack of randomized controlled trials comparing 
the different treatment modalities for oral leukoplakia 
is a major dilemma for oral and maxillofacial surgeons. 
Several comparative studies have reported that there 
are no effective treatment procedures to prevent malig-
nant transformation of oral leukoplakia61–63.  The risk of 
cancer development could not be signiﬁ cantly reduced 
by surgical intervention39,43,64,65.  The malignant trans-
formation rates of oral leukoplakia appeared to be lower 
in the patients diagnosed by health examination in In-
dia who had no treatment as compared with in-pa-
tients32.  Silverman et al.21 found only 6 cases of malig-
nant transformation in 4,762 patients with oral 
leukoplakia receiving no treatment over a 2-year period. 
Nevertheless, as our previous ﬁ ndings showed that the 
malignant transformation rate of leukoplakia treated 
by surgery was signiﬁ cantly lower than that without 
any treatment or that without surgery (Table 10), we 
believe that surgical excision with an adequate safety 
margin, coupled with well-timed evaluation of oral leu-
koplakia on follow-up, is effective in preventing the ma-
lignant transformation of these lesions33.  Our ﬁ ndings 
are supported by some other reports66,67.
 Roodenburg et al.68 treated oral leukoplakia of 70 pa-
tients with carbon dioxide laser evaporation and evalu-
ated the outcome up to a 12-year period (mean 5.3 
years).  Most patients (90%) had no recurrence of oral 
leukoplakia and no malignant transformation was ob-
served in any case.  This is in support of one report69 
and in contrast to another40.  Although vitamin A and 
Table 10　Malignant transformation rates according to treatment33
Treatment No. of cases
No. of malignant transformation 
(%)
Surgery
Chemotherapy
Chemotherapy and surgery
Radiation
None
 94
 13
 13
  5
 44
1  (1.1)
2 (15.4)
1  (7.7)
1 (20.0)
7 (15.9)
Total 169 12  (7.1)
* Malignant transformation rate of leukoplakia treated by surgery was signiﬁ cantly 
lower than that without any treatment (p＜0.01) or that without surgery (p＜0.01).
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other retinoids70 or topical bleomycin71 are used for the 
therapy of leukoplakia, these were reported to have only 
a limited effect in controlling oral leukoplakia and in 
preventing malignant transformation.
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